BioSpace News Archive

SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, announces the appointment of Joseph C.

Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license agreement with Merck & Co Inc., Rahway, N.J., USA, known as MSD outside the U.S. and Canada, to jointly identify and develop molecular glue degraders against multiple therapeutic targets.

Tonix Pharmaceuticals Holding Corp. announced that two posters with research results on TNX-1700 will be presented as posters at the American Association for Cancer Research Annual Meeting being held April 14-19, 2023, in Orlando, Fla.

Bio-Techne Corporation announced it that it has reached a significant milestone with more than 1,000 Ella™ automated immunoassay instruments now in the field.

Ginkgo Bioworks announced the acquisition of StrideBio’s adeno-associated virus capsid discovery and engineering platform assets with a secondary close scheduled upon the transfer of certain additional in-license agreements to Ginkgo.

Enanta Pharmaceuticals, Inc. announced that data for EDP-235, its lead 3CL protease inhibitor specifically designed as an oral, once-daily treatment for COVID-19, and EDP-323, its L-protein inhibitor in development for the treatment of respiratory syncytial virus, will be presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases being held April 15-18 both virtually and at the Bella Center Copenhagen in Copenhagen, Denmark.

ZAP Surgical Systems, Inc. today announced that the company received regulatory approval in India for its first ZAP-X® Gyroscopic Radiosurgery® platform in the form of a No Objection Certificate (NOC) from the Atomic Energy Regulatory Board (AERB).

Generation Bio Co., a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary.

Soligenix, Inc. announced today that the United States Adopted Names (USAN) Council has approved the use of the nonproprietary name of “hypericin sodium” for the novel active ingredient in both HyBryte™ (research name SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL) and SGX302 for the treatment of mild-to-moderate psoriasis.

Exegenesis Bio, a rapidly growing global gene therapy company is pleased to announce the presentation of five posters at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Los Angeles, California, May 16 to 20, 2023.